One year in review 2018: novelties in the treatment of rheumatoid arthritis

被引：1
|
作者：
Bortoluzzi, A. [1 ]
Furini, F. [1 ]
Generali, E. [2 ]
Silvagni, E. [1 ]
Luciano, N. [3 ]
Scire, C. A. [1 ,4 ]
机构：
[1] Univ Ferrara, Rheumatol Unit, Dept Med Sci, Ferrara, Italy
[2] Humanitas Clin & Res Ctr, Div Rheumatol & Clin Immunol, Milan, Italy
[3] Univ Pisa, Rheumatol Unit, Dept Clin & Expt Med, Pisa, Italy
[4] Italian Soc Rheumatol, Epidemiol Unit, Milan, Italy
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2018年 / 36卷 / 03期
关键词：
rheumatoid arthritis; biologics; treatment; management; TUMOR-NECROSIS-FACTOR; MODIFYING ANTIRHEUMATIC DRUGS; LONG-TERM EFFECTIVENESS; RANDOMIZED PHASE IIB; LOW DISEASE-ACTIVITY; DOUBLE-BLIND; OPEN-LABEL; MONOCLONAL-ANTIBODY; CLINICAL-OUTCOMES; INADEQUATE RESPONSE;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The current approach to treatment of rheumatoid arthritis (RA) includes early and aggressive intervention aiming to reach early and persistent low disease activity and remission. New drugs have improved the therapeutic armamentarium of rheumatologists, providing new options for patients. Beyond these innovations, new evidence has improved the safety of therapies and provided tools for the optimisation of long-term management of RA. This paper reviews the most relevant studies published over the last year in the field of treatment of RA.
引用
收藏
页码：347 / 361
页数：15
相关论文
共 50 条
  • [41] IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review
    Ogata, Atsushi
    Kato, Yasuhiro
    Higa, Shinji
    Yoshizaki, Kazuyuki
    MODERN RHEUMATOLOGY, 2019, 29 (02) : 258 - 267
  • [42] Tofacitinib for the treatment of rheumatoid arthritis
    Zerbini, Cristiano A. F.
    Vannucci Lomonte, Andrea Barranjard
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2012, 8 (04) : 319 - 331
  • [43] Rheumatoid Arthritis Activity and Treatment
    Urbina Aucancela, Cynthia Yesenia
    Carrera Montero, Geyla Yomar
    Quintana Dominguez, Omar Santiago
    Guama Bonilla, Lucia Nataly
    REVISTA CUBANA DE REUMATOLOGIA, 2020, 22 (03):
  • [44] Current treatment of rheumatoid arthritis
    Carli, P.
    Landais, C.
    Aletti, M.
    Cournac, J. -M.
    Poisnel, E.
    Paris, J. -F.
    REVUE DE MEDECINE INTERNE, 2009, 30 (12): : 1067 - 1079
  • [45] Evolution of treatment for rheumatoid arthritis
    Upchurch, Katherine S.
    Kay, Jonathan
    RHEUMATOLOGY, 2012, 51 : 28 - 36
  • [46] Challenges in the treatment of Rheumatoid Arthritis
    Conigliaro, Paola
    Triggianese, Paola
    De Martino, Erica
    Fonti, Giulia Lavinia
    Chimenti, Maria Sole
    Sunzini, Flavia
    Viola, Alessandra
    Canofari, Claudia
    Perricone, Roberto
    AUTOIMMUNITY REVIEWS, 2019, 18 (07) : 706 - 713
  • [47] Pharmacogenetics in Treatment of Rheumatoid Arthritis
    Kooloos, W. M.
    Huizinga, T. W. J.
    Guchelaar, H. -J.
    Wessels, J. A. M.
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (02) : 164 - 175
  • [48] Filgotinib for the treatment of rheumatoid arthritis
    Taylor, Peter C.
    Azeez, Maha Abdul
    Kiriakidis, Serafim
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (10) : 1181 - 1187
  • [49] One year in review 2018: systemic lupus erythematosus
    Di Battista, M.
    Marcucci, E.
    Elefante, E.
    Tripoli, A.
    Governato, G.
    Zucchi, D.
    Tani, C.
    Alunno, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (05) : 763 - 777
  • [50] Current and Emerging DMARDs for the C Treatment of Rheumatoid Arthritis
    Mysler, Eduardo
    Caubet, Mariana
    Lizarraga, Ana
    OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2021, 13 : 139 - 152
12345